Build and sustain strong multi-level relationships with healthcare decision-makers, including P&T and formulary committee members, executive pharmacy leadership, C-suite executives, and service line leaders, across key oncology accounts (IDNs, Academic Centers, regional health systems, and community network parent organizations). HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.